In Russia, a Shortage of a Vital Drug is Expected
OREANDA-NEWS. The Ministry of Industry and Trade has warned of the risk of immunoglobulin deficiency in Russia. The reason for this is the low marginal selling price and the lack of raw materials for its production, Izvestia writes.
The drug is vital for patients with primary immunodeficiency, which leads to severe chronic infections, inflammatory damage to organs and tissues, and an increased frequency of autoimmune and oncological diseases. Therapy is prescribed for life.
Immunoglobulin deficiency was noticed by patients in 80 percent of the regions of the country. Academician of the Russian Academy of Sciences Alexander Rumyantsev noted that due to the pandemic, the activity of donors has decreased and there is not enough raw material - blood plasma. At the same time, the consumption of immunoglobulin increased due to patients with coronavirus.
Earlier it was reported that the Russians rushed to buy medicines, as during the outbreak of the coronavirus pandemic. According to Kommersant, in the first half of 2021, pharmaceutical retailers practically managed to keep their revenue turnover at last year's level. From January to June, pharmacies earned 552.1 billion rubles: just 1 percent less than in the same period of 2020.
Retailers managed to keep the indicators due to the growth of prices for medicines and against the background of the incessant demand for drugs that are used in the treatment of coronavirus. Internet sales also increased.